Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:4.6.1.1 (
adenylate cyclase
)
19,190
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Increase of blood capillary density at the interface between normal and ischemic tissue after acute MI reduces infarct size and improves cardiac function. Cardiac injury triggers the production of the matricellular component
TSP-1
, but its role in angiogenesis is not clear, as both anti- and proangiogenic properties have been reported. It is unknown whether
TSP-1
is modulated by other factors released during cardiac injury. Among these, Ado is a well-known promoter of angiogenesis. This study determined whether Ado modulates
TSP-1
expression and the implication on angiogenesis. Ado dose dependently increased the production of
TSP-1
by human macrophages. With the use of agonists and antagonists of AdoRs, coupled to RNA interference, we observed that this effect is mediated via A2AR and A2BR. The Ado effect was reproduced by cholera toxin (Gs protein activator) and forskolin (
adenylate cyclase
activator) and blocked by the PKA inhibitor H89. Conditioned medium from Ado-treated macrophages stimulated microvessel outgrowth from aortic ring explants by 400%, and induced vessel formation in matrigel plugs. Microvessel outgrowth and vessel formation were blocked completely by addition of anti-
TSP-1
antibodies to conditioned medium. Chronic administration of Ado to rats after MI maintained long-term expression of
TSP-1
in the infarct border zone, and this was associated with enhanced border-zone vascularization. Ado up-regulates
TSP-1
production by macrophages, resulting in stimulation of angiogenesis. The mechanism involves A2AR and A2BR and is mediated through the cAMP/PKA pathway. This information may be important when designing Ado-based therapies of angiogenesis.
...
PMID:Adenosine stimulates angiogenesis by up-regulating production of thrombospondin-1 by macrophages. 2556 40